spleen transplantation
1.The hBM-MSCs reside mainly in the bone marrow, liver and spleen in the early stage following transplantation, homing into the bone marrow and skeletal muscle later.
2.Objective:To study the mechanism of immune tolerance induce by protal venous injection of donor spleen cells on the dog model of renal transplantation.
3.Gene modified FLC (FLC GM) labeled with 111 In were injected into the allogenic mice, spleen, the %ID/g of liver was 20%～25% at 24 hr and 50%～55% at 48 hr after transplantation.
4.Afterwards mice of donor lymphocyte infusions(DLI) group received 5×106, 1×107, 2×107 spleen cells from donor mice. The engrafment of allograft, graft versus host disease(GVHD), the survival days and transplantation-related complications were observed.
5.Experimental Study on the Prevention for Post-transplantation Recurrence of Hepatocellular Carcinoma with Adoptive Immunotherapy from Dendritic Cells Induced Donor Spleen Lymphocytes
6.The results showed that the GVT response of transplantation was reduced after in vitro depletion of T and NK cells or blocking NKG2D receptor in donor cells of the graft, the expression levels of RAE-1 and H60 mRNA in tumor tissue increased after transplantation of haploidential bone marrow mixed with spleen cells.
7.Methods: The orthotopic liver transplantation models of spontaneous tolerance were established between BN (donor) and LEW (recipient) inbred rats whose survival time was more than 120 days, The expression of CD8+CD28- T and CD4+CD25+T cells in PBMC and spleen were determined by flow cytometry.
8.The dentritic cells modified with α-MSH gene,named α-MSH-DC,were injected into the recipient C57BL/6 mice 7 days before transplantation. The existence of the donor α-MSH-DC in the recipient animal spleens was studied by immunohistochemistry. The hyporesponsiveness of the recipient spleen T-cell to the donor alloantigen was determined by mixed lymphocyte reaction(MLR).
